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Abstract
For three decades, the Expanded Programme on Immunization (EPI) has been
promoted as one of the key child health interventions in developing countries. Vac-
cines for six childhood diseases (diphtheria, measles, pertussis, poliomyelitis, teta-
nus, and tuberculosis) have been shown to be efficacious in preventing disease-spe-
cific morbidity and mortality, yet not all commentators are convinced that the EPI
reduces all-cause child mortality. Numerous studies have found that measles vacci-
nation programs substantially reduce all-cause child mortality, but recent findings
from Guinea-Bissau suggest that diphtheria, pertussis, and tetanus (DPT) vaccine
may increase all-cause child mortality.
The present study uses five years of data from the Navrongo Demographic
Surveillance System, a longitudinal population registration system in northern Ghana,
to examine all-cause mortality among vaccinated and unvaccinated children under 5
years of age. The data indicate that coverage by one Bacillus Calmette-Guérin (BCG)
shot, three sets of polio drops, and three DPT shots reduces mortality between ages
4 and 8 months by nearly 90 percent. Complete coverage by all EPI antigens reduces
mortality between ages 9 and 59 months by 70 percent. BCG, polio, and DPT vac-
cines without measles vaccination reduce mortality by 40 percent. The independent
reduction in mortality associated with measles vaccination is 50 percent. Our data
add to a growing body of evidence that suggests that measles vaccination programs
reduce all-cause mortality substantially beyond the proportion of deaths caused by
measles. These results indicate a need for further research in developing countries
on the all-cause mortality impact of these vaccines, in particular DPT vaccine.
Despite recent improvements in child survival in Ghana, mortality levels are still
very high. The estimated national infant mortality rate is 57 per 1,000 live births while
under-5 mortality is 108 per 1,000 live births (Ghana Statistical Service and Macro
International 1999). In rural settings where health services are not accessible to a large
proportion of the population, the situation is even worse. In Kassena-Nankana District,
a typical rural Guinea savannah area, infant and under-5 mortality rates for 1999 are
90.0 and 151.9 per 1,000 live births, respectively. These levels are exceptionally high as
compared to estimated national figures. Furthermore, more than 60 percent of children
in the district die of preventable diseases (Binka et al. 1995).
In response to the worldwide call to improve child survival, the Expanded
Programme on Immunization (EPI) advocated by UNICEF was wholly embraced by
Ghana in the early 1980s. As in most developing countries, immunization against the six
immunizable childhood diseases (i.e., diphtheria, measles, pertussis, poliomyelitis, teta-
nus, and tuberculosis) has been instituted as part of Ghana’s primary health care pro-
gram. Access to the antigens is mainly through outreach programs, particularly in re-
mote areas, and through routine child clinic sessions at health care facilities. While the
EPI in Ghana in the early 1980s was described as a great success, falling coverage rates
characterized the period 1986–91 (UNICEF 1993). In the last decade, however, Ghana
has experienced a modest upturn in full vaccination rates, from 55 percent in 1993 to 62
percent in 1998 for all one-year-olds (Ghana Statistical Service and Macro International
1999). Despite this improvement, the worldwide target of 90 percent coverage by the
year 2000 is far from being attained.
The lack of reliable data on EPI-targeted diseases as causes of death makes it
difficult to assess the magnitude of mortality reductions due to immunization uptake. It
has been argued that reductions in disease-specific mortality will not necessarily trans-
late into improvements in child survival in situations where children are at high risk of
death from other causes. This argument holds that those “saved” by immunization may
be weaker, on average, than those who would have survived without immunization, and
therefore more likely to die of other causes (Koenig, Fauveau, and Wojtyniak 1991;
Mosley and Chen 1984; Kasongo Project Team 1981). Others have argued against this
4view, claiming that immunization prevents not only death but also illness, thereby pro-
moting the overall health of the child and reducing mortality by more than the share of
deaths directly attributable to the targeted diseases (Kristensen, Aaby, and Jensen 2000;
Aaby 1995; Koenig et al. 1991). Further, immunization drives could affect mortality
through behavioral as well as biomedical pathways. Health workers generally use desig-
nated national immunization days (NIDs) to measure and weigh children and provide a
wide range of health-related information. NIDs serve as a contact point with the official
health care system for mothers, especially in rural areas, who might otherwise rarely
interact with the system.
However, logistical difficulties, particularly in settings such as rural northern
Ghana, may limit an immunization program’s potential for impact. In most rural areas,
the schedules for EPI outreach may not correspond to the exact time at which a child is
due for a particular antigen. For maximum protection against the six childhood killer
diseases, it is recommended that a child receive one dose of Bacillus Calmette-Guérin
(BCG) at birth; three doses of diphtheria, pertussis, and tetanus (DPT) vaccine and polio
drops at ages 6, 10, and 14 weeks; and the measles vaccine at age 9 months. Outreach
programs are usually planned to correspond to days of local activity (such as market
days, nonfarming/nonfishing days, and so forth) and at reasonable intervals to ensure
adequate response to the call to send children to outreach points. Complete uptake may,
therefore, not necessarily result in improvements in child survival because vaccinations
may be mistimed. In other situations, mothers may fail to return for later vaccines. This
is particularly true for the measles vaccine, which should be given nearly six months
after completion of the rest of the series. Thus, the full benefit of the immunization
routine for the child may not be achieved.
In addition, vaccines may lose their sensitivity during transportation between a
health institution and an outreach point because of unsatisfactory storage facilities. Most
vaccines need to be stored at low temperatures to maintain their potency. In cases where
the cold chain is broken due to unavailability of refrigeration facilities, the antigen may
have lost its effectiveness by the time it is administered to a child. This problem of
transporting vaccines under unsatisfactory conditions is often encountered in rural areas.
5In Kassena-Nankana District, however, efforts are made to maintain the cold chain by
providing vaccines to nurses just before they begin their outreach duties. Nevertheless,
considering that the climate in the district is very hot and temperatures can reach 40°C,
even an hour’s drive to an outreach point can break the cold chain.
The aim of this paper is to examine the influence of immunization coverage on
all-cause child mortality in Kassena-Nankana District of northern Ghana. Five years of
longitudinal data on child survival and immunization status permit a detailed analysis of
the mortality experiences of children who have received none, some, or all of the EPI-
recommended immunizations.
SOURCE OF DATA AND SAMPLE SELECTIVITY
The data used for the analysis are based on the Navrongo Demographic Surveil-
lance System (NDSS). The NDSS is a longitudinal population registration system estab-
lished in Kassena-Nankana District in 1993 to support research into rural health prob-
lems and to provide a means for testing various health intervention strategies. Surveillance
activities began with a baseline census in July 1993. Since then, demographic events
have been continuously updated through visits to village compounds at 90-day inter-
vals. Data are collected on births, deaths, in- and out-migration, marriages, and preg-
nancies. Also included in the database is basic demographic information such as sex,
dates of events, and relationships of household members.
In addition, data on vaccination status have been collected annually beginning in
1996 for children less than 2 years of age at the time of interview. The interviewer
records dates of vaccination only if the mother has a health card or some other written
record of the date and the vaccination given. This means that some of the children clas-
sified as not vaccinated may in fact have received vaccinations but lost their health cards
by the time of the survey. Between 50 and 60 percent of children had a health card or
other written record in each of the four surveys from 1996 to 1999. The data used in this
paper include children who were born in the study area between 1 October 1994 and 31
December 1999 and for whom information is available in at least one of the vaccination
surveys. Children who were born elsewhere and migrated into the study area were excluded
6even if information on them was available in one of the vaccination surveys. Because of
the high level of out-migration in the district, some children are likely to be missed in
these vaccination surveys in early childhood; even if they return they may then be too
old to qualify for inclusion. In addition, because the annual vaccination survey collects
information only on living children, children who were born and then died between
successive surveys are not included in the vaccination database.
Table 1 compares background characteristics of the children in the main NDSS
database with those included in the vaccination surveillance database in order to pro-
vide an idea of the selectivity of the sample used for the analysis. The cells indicated in
the table refer to the Community Health and Family Planning Project (CHFP) experi-
ment cells representing alternative approaches to primary health care delivery in geo-
graphically contiguous areas (Binka, Nazzar, and Phillips 1995). Each cell corresponds
to the catchment area of a health center in Kassena-Nankana District. The “Zurugelu”
intervention in Cell 1 seeks to increase community involvement in health decisions by
involving traditional village structures (chiefs, elders, and soothsayers) and volunteers
in planning and delivering health activities and services and introducing project mes-
sages into traditional community meetings. The strategy for Cell 2 involves reorienta-
tion and relocation of community health nurses from the health centers to community
health centers in the villages, where they both live and work. Cell 3 combines the Cell 1
and Cell 2 strategies. Cell 4 is the comparison area, in which both the Zurugelu and
relocated nurses are absent, and only the normal Ministry of Health approach to health
delivery operates (i.e., a health center with outreach to communities). Cell 5, the only
urban section of the district, is not included in the CHFP. However, demographic sur-
veillance and vaccination data are collected in this area.
From Table 1, it is evident that the sample used for the analysis is comparable to
the main child database on sex, cell of residence, and number of compound residents.
The disparity in the distribution of age at first observation is due to the fact that the
analysis is restricted to those born in the study area. Maternal and paternal characteris-
tics are unknown for a smaller proportion of those included in the analysis compared to
those not included, which is also a result of the fact that only children followed from
birth are included in the analysis.
7The bias in the selected sample with respect to the survival status of the child is
also to be expected because the immunization schedule is administered only once a year
to surviving children. Children who are born and die between two surveys (i.e., many of
those who die in the neonatal and early post-neonatal periods, when a large fraction of
under-5 mortality occurs) do not appear in the vaccination database. This analysis is
therefore biased toward surviving children between the ages of 0 and 9 months. The
table indicates that survival of children from 9 to 59 months is comparable between
those included and those excluded, however. This bias therefore does not affect analysis
restricted to the 9–59-month age group.
Table 1 indicates that mother’s information is missing for 0.3 percent of the chil-
dren. These children were subsequently excluded from the study, bringing the final sample
to 17,701. The fathers of approximately 12 percent of the children are unknown. For this
reason, paternal education and residence are not included as explanatory variables in the
analysis.
METHODS OF ANALYSIS
A central question in planning this analysis concerns the definition of vaccination
coverage. An appealing approach would be to simply create one indicator variable for
each of the eight EPI antigens (BCG; polio 1, 2, and 3; DPT 1, 2, and 3; and measles) to
indicate whether a child had received that antigen at a given age. Regression techniques
could then be used to assess the independent contribution of each of the antigens to
survival while holding constant the other seven, and to assess the combined mortality
impact of the full EPI package. However, these eight variables are extremely highly
correlated for obvious reasons: polio 1 and DPT 1 are given at the same time, and the
mother who has taken her child to the clinic to receive the first set of shots is more likely
to take the child back to receive the second set. Such high correlations between explana-
tory variables make it impractical to consider each antigen separately.
Research from other studies has demonstrated substantial reductions in mortality
associated with measles immunization programs (Aaby 1995; Koenig, Fauveau, and
Wojtyniak 1991). We therefore considered it important to assess the independent contri-
bution of measles immunization to survival in this population. Because BCG, polio, and
8Table 1 Distribution of children included and not included in the analysis by back-
ground characteristics
Percent distribution of children
Background Children included Children not included All children
characteristic in analysis in analysis in study area
Survival status of child
All ages (0–59 months)
Alive 91.2 77.0 87.5
Dead 8.8 23.0 12.5
9–59 months
Alive 93.9 94.0 93.9
Dead 6.1 6.0 6.1
Sex of child
Male 49.9 49.4 49.7
Female 50.1 50.6 50.3
Cell location
Cell 1 15.0 13.6 14.7
Cell 2 14.7 13.6 14.4
Cell 3 32.6 29.2 31.7
Cell 4 32.5 31.7 32.3
Cell 5 5.2 12.0 7.0
Mother’s age at birth
of child (years)
15–19 11.2 11.6 11.3
20–24 21.9 23.6 22.4
25–29 22.5 20.8 22.0
30–34 19.4 16.6 18.7
35–39 15.6 11.1 14.4
40+ 9.1 6.5 8.4
Missing 0.3 9.8 2.8
Mother’s education
None 83.7 71.6 80.5
Some 16.0 18.6 16.7
Missing 0.3 9.8 2.8
continued
9Table 1 continued
Percent distribution of children
Background Children included Children not included All children
characteristic in analysis in analysis in study area
Mother’s residence
Always resident 87.1 77.1 84.5
Sometimes resident 6.5 6.5 6.5
Never resident 6.1 6.6 6.2
Missing 0.3 9.8 2.8
Father’s education
None 70.4 50.0 65.1
Some 17.9 15.8 17.3
Missing 11.7 34.2 17.6
Father’s residence
Always resident 63.8 45.4 59.0
Sometimes resident 14.5 7.3 12.6
Never resident 10.0 13.0 10.8
Missing 11.7 34.2 17.6
Mean compound membersa
2–8 22.2 25.0 23.0
9–13 23.7 25.0 24.0
14–22 28.3 27.7 28.1
23+ 25.8 22.3 24.9
Age at first observation
(months)b
0 100.0 47.1 86.2
1–11 0.0 26.1 6.8
12–23 0.0 13.7 3.6
24–35 0.0 8.0 2.1
36–47 0.0 3.5 0.9
48–59 0.0 1.5 0.4
Total number of children 17,753 6,300 24,053
a Mean number of compound members during observation of child.
b
 Age of child at first observation (beginning of study, birth, or in-migration).
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DPT coverage are so highly correlated, we decided to consider them as a single pack-
age. Vaccination coverage is therefore defined first by whether the child has received
no, partial, or full BCG/polio/DPT coverage, and second by whether the child has re-
ceived the measles vaccine. This typology is illustrated in Figure 1. Only 14 children,
representing 0.05 percent of the total person-time of observation, received the measles
vaccine but none of the BCG/polio/DPT series. Since these were too few cases to form
a separate category, these children were included in Group 0 until the time of their
measles vaccination and then censored.
Kaplan-Meier survival functions and mortality rates (ratio of number of deaths to
person-years of observation) for different age groups are used to examine differences in
childhood mortality between the five categories of vaccination coverage described in Fig-
ure 1. Confidence intervals for rate ratios are calculated following Kelsey and colleagues
(1996). Specifically, the variance of the log rate ratio is estimated as (1/d0 + 1/d1), where d0
and d1 refer to the number of events (deaths) in the two groups being compared.
A discrete-time hazards regression model is then used to estimate the effect of
vaccination coverage on survival while controlling for potential confounding variables.
In a hazards model, the risk of death is modeled as a function of time (in this case, age of
the child) and other characteristics. The model accounts for censored survival times and
allows individual characteristics to change over time. In this analysis, a censored child
is one who survives until the end of observation or one who does not experience the
BCG/polio/DPT seriesa
None Partial Full
Group 0 Group 1 Group 2
— Group 3 Group 4
No
YesM
ea
sle
s
v
a
cc
in
at
io
n
Figure 1 Vaccination coverage categories
a
 Complete series consists of one BCG shot, three sets of polio drops, and three DPT shots.
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event of death before being lost to follow-up, as in the case of out-migrant children.
Uncensored children, on the other hand, are those who experience the event of death at
the specified time.
The data for a discrete-time model are first structured as a series of Bernoulli
trials, one for each discrete month; therefore, the covariates for a given child can assume
different values from one month to the next. Thus a separate record is created for each
unit of time for which the child is known to be at risk of death. A child who survives the
first 5 years of life, for example, will have 60 records, while the child who dies at age 5
months will have 5 records. For each person-month, the dependent variable (survival
status) is coded 1 if the child died during that month and 0 if the child survived. The
discrete-time model can thus be fitted using any model for binary response data. Using
the logit link, the probability of death hit for child i at time t is given by:
hit
x
x
t it
t it
=
+
+ ′( )
+ ′( )
exp
exp
α β
α β1
where αt is a function of time, x′it is a vector of covariates, and β is a vector of param-
eters to be estimated.
The relationship of the outcome variable with time, α
t
, can be modeled in several
ways. The simplest approach is to assume a constant relationship over time, for ex-
ample, α
t 
= α. Other choices include a linear function of time, α
t 
= α0 + α1t; a quadratic
function, αt = α0 + α1t + α2t2; or a log-linear relationship, αt = α0 + α1log(t). In this case,
separate models were estimated for children aged 4–8 months and 9–59 months. In each
model, exploratory analyses indicated that the linear function of age was the most ap-
propriate, as it yielded a better fit than the logarithmic transformation of age and the
addition of a quadratic term did not contribute significantly to the fit of the model.
Other explanatory variables considered for inclusion in the model are the child’s
sex and year of birth; the mother’s age, education, and residential status; number of
residents in the compound; cell location of the child; and distance to the nearest health
facility and to Navrongo Town (the only urban center in the district). The mother’s age
at birth of the child, the year of birth of the child, and the number of compound residents
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are categorized, while sex of the child and maternal education and residence are repre-
sented by indicator variables. Logarithms were taken of the distance variables to nor-
malize their highly skewed distributions.
Models were first specified using all potential explanatory variables. Variables
with coefficients not significantly different from 0 at the 95 percent confidence level
were removed one at a time, but were replaced if their removal caused any of the statis-
tically significant coefficients to change by 10 percent or more. Certain variables con-
sidered to be of programmatic importance (such as the experimental cell of residence)
were retained regardless of their level of statistical significance. To aid in the interpreta-
tion of the regression analysis, coefficients are exponentiated and presented as odds ratios.
RESULTS
Immunization uptake and timing in the first year of life
Table 2 shows the percentage of children immunized, the percentage receiving
each vaccination at the recommended age, and the median age at vaccination among
children who survived to the age of 12 months. If immunization does indeed reduce
mortality, this table will overestimate actual coverage rates achieved, as there will be a
higher proportion of immunized children among those who survive to age 12 months
than among those who survive to the recommended age of immunization but die before
age 12 months. As expected, vaccination rates are higher for vaccines received earlier in
life, such as BCG, polio 1, and DPT 1. Although the uptake of measles vaccination is quite
low, it appears to have the most strictly followed schedule. The last two columns of Table 2
indicate that a majority of children in the study population receive BCG, polio, and DPT
vaccinations at a later age than is recommended (often a month or more later).
Childhood mortality rates
Figure 2 illustrates the differences in mortality risks during childhood between
the five vaccination status categories. Figure 2a compares the monthly mortality risk for
months 4–8 (expressed as the number of deaths per 1,000 population at risk each month)
for vaccination status Groups 0, 1, and 2 (those with no, partial, or full BCG/polio/DPT
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coverage, respectively, and no measles coverage). Children under 4 months of age are
excluded because they will not have had time to complete the polio and DPT series, and
Groups 3 and 4 are not considered because there are too few children immunized against
measles prior to age 9 months to make comparison of mortality risks meaningful. Those
who were vaccinated against measles prior to age 9 months were censored at that time
for the purposes of this graph. Figures 2b and 2c compare monthly mortality risks for all
five vaccination status groups for ages 9–23 and 24–59 months, respectively. The low
numbers of deaths at later ages makes the month-by-month mortality risks somewhat
erratic and difficult to compare. For ease of interpretation, therefore, Figure 2b presents
average monthly mortality risks for three-month age groups (9–11, 12–14, and so forth),
and Figure 2c shows average monthly risks for six-month age groups (24–29, 30–35,
and so forth).
It is apparent from Figures 2a and 2b that children who have received no immu-
nizations are at substantially higher risk of death through approximately the first year of
life than those who have some vaccination coverage, whether complete or incomplete.
Those who have received some or all of the BCG/polio/DPT series (Groups 1 and 2)
Table 2 Immunization rates by age 12 months
Percentage of Percentage
children immunized  of immunized Median age at
by age 12 months children who received vaccination
Vaccination type (N=13,164)a timely vaccinationsb (months)
BCG 71.7 36.3 (9,443) 1.6
Polio 1 73.6 42.6 (9,690) 2.2
Polio 2 65.6 27.3 (8,631) 3.9
Polio 3 53.0 19.0 (6,973) 5.2
DPT 1 72.6 36.5 (9,553) 2.4
DPT 2 65.5 24.2 (8,628) 3.9
DPT 3 56.3 16.5 (7,412) 5.5
Measles 45.1 75.1 (5,941) 9.1
a
 Excludes children born in 1999.
b
 N is shown in parentheses.
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vaccine; Group 2 = Full BCG/polio/DPT coverage, no measles vaccine; Group 3 = Partial BCG/
polio/DPT coverage, measles vaccine; Group 4 = All immunizations (full BCG/polio/DPT cover-
age, measles vaccine).
Figure 2  continued
c Ages 24–59 months
face mortality risks approximately one-fourth to one-tenth those of the unvaccinated
group (Group 0) in months 4–8 (Figure 2a) as well as in the 9–11-month age group
(Figure 2b). During the second year of life (Figure 2b), little difference is evident be-
tween unvaccinated children and those who have received some or all of the BCG/polio/
DPT series without the measles vaccine. Those who have received the measles vaccine
(Groups 3 and 4), whether or not they have completed the BCG/polio/DPT series, face
mortality risks approximately half as high as unvaccinated children and children in Groups
1 and 2 during the same period. In the third year of life (months 24–29 and 30–35),
mortality is lower in most of the vaccinated groups relative to the unvaccinated, al-
though the differences are generally small. In the fourth and fifth years of life, when
mortality is low overall, there is little difference between the five groups.
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Figure 3 Kaplan-Meier survival functions by vaccination status
a Ages 4–8 months
b Ages 9–59 months
Note: Group 0 = No immunizations; Group 1 = Partial BCG/polio/DPT coverage, no measles
vaccine; Group 2 = Full BCG/polio/DPT coverage, no measles vaccine; Group 3 = Partial BCG/
polio/DPT coverage, measles vaccine; Group 4 = All immunizations (full BCG/polio/DPT cover-
age, measles vaccine).
1.00
0.98
0.96
0.94
0.92
0.90
Pr
o
ba
bi
lit
y 
of
 su
rv
iv
a
l,
gi
v
en
 s
u
rv
iv
a
l t
o 
ag
e 
4 
m
on
th
s
Age (months)
4 5 6 7 8
Group 2
Group 1
Group 0
1.00
0.98
0.96
0.94
0.92
0.90
0.88
0.86
0.84
Pr
o
ba
bi
lit
y 
of
 su
rv
iv
a
l,
gi
v
en
 s
u
rv
iv
a
l t
o 
ag
e 
9 
m
on
th
s
Age (months)
12 24 36 48 60
Group 4
Group 3
Group 2
Group 1
Group 0
17
Even though the mortality differentials in later childhood are small, the differ-
ences in infancy and early childhood lead to substantially higher cumulative under-5
survival for vaccinated children than for unvaccinated children. Figure 3 shows Kaplan-
Meier survival functions by vaccination status. Figure 3a examines Groups 0, 1, and 2
over the 4–8-month age range, while Figure 3b compares all five groups from 9 to 59
months. There is a clear trend linking more complete vaccination coverage with in-
creased probability of survival until the fifth birthday.
Table 3 presents rate ratios summarizing the total gain in survival in late infancy
and childhood associated with vaccination status. Mortality rates for each group over
each age range were calculated as the number of deaths divided by person-years of
observation; within each age range, the rates for each of Groups 1–4 were then divided
by the rate for Group 0 to obtain these ratios. Ninety-five percent confidence intervals
for the rate ratios are shown in parentheses.
The calculated confidence intervals indicate that almost all rate ratios are signifi-
cantly lower than 1.00 at the 95 percent confidence level. The only exceptions are rate
ratios comparing Groups 1 and 2 to Group 0 (the unvaccinated children) at ages 12–23
months and comparing Group 3 to Group 0 at ages 24–59 months, for which the confi-
dence intervals include 1.
Over the age range 9–59 months, the total reduction in mortality associated with
immunization ranges from 25 percent for children with partial BCG/polio/DPT cover-
age and no measles vaccination to 70 percent for those with the full complement of
UNICEF-recommended vaccinations. The incremental reduction in mortality over this
age range associated with measles vaccination alone is around 50 percent, as can be
seen by comparing groups with comparable BCG/polio/DPT status but different measles
vaccination status. The rate ratio (RR) comparing Group 3 to Group 1 for children ages
9–59 months is 0.54 (95% CI = [0.39, 0.73]), and the RR comparing Group 4 to Group
2 is 0.50 (95% CI = [0.40, 0.64]). It is counter-intuitive that at 24–59 months, those who
received the measles vaccine experienced higher mortality than those with comparable
BCG/polio/DPT coverage but no measles vaccine. However, mortality rates in this age
range have large standard errors due to the small number of deaths, and statistical tests do
not allow us to conclude that mortality differs significantly between children vaccinated
18
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Table 4 Discrete-time hazards regression model for examining the effect of the degree
of immunization uptake and mortality in the 4–8-month age group
Variable Coefficient Standard error P-value Odds ratio 95% CI
Age (months) 0.0528 0.0375 0.159 1.05 (0.98, 1.13)
Vaccination status
Group 0a 0.0000 — — 1.00 —
Group 1 –1.4424 0.1251 <0.001 0.24 (0.18, 0.30)
Group 2 –2.3958 0.2264 <0.001 0.09 (0.06, 0.14)
Sex of child
Femalea 0.0000 — — 1.00 —
Male –0.0996 0.1049 0.342 0.91 (0.74, 1.11)
Mother’s age at birth
of child (years)
15–19 0.4322 0.2058 0.036 1.54 (1.03, 2.31)
20–24 0.1770 0.1736 0.308 1.19 (0.85, 1.68)
25–29a 0.0000 — — 1.00 —
30–34 0.2940 0.1727 0.089 1.34 (0.96, 1.88)
35–39 0.4397 0.1741 0.012 1.55 (1.10, 2.18)
40+ 0.4250 0.1941 0.029 1.53 (1.05, 2.24)
Residence
Cell 1 0.3255 0.1624 0.045 1.38 (1.01, 1.90)
Cell 2 0.4850 0.1536 0.002 1.62 (1.20, 2.19)
Cell 3 0.1132 0.1348 0.401 1.12 (0.86, 1.46)
Cell 4a 0.0000 — — 1.00 —
Cell 5 –0.2197 0.2931 0.453 0.80 (0.45, 1.43)
Year of birth
1996a 0.0000 — — 1.00 —
1997 –0.2091 0.1416 0.140 0.81 (0.61, 1.07)
1998 –0.0726 0.1473 0.622 0.93 (0.70, 1.24)
1999 0.2545 0.1446 0.078 1.29 (0.97, 1.71)
Constant –4.9012 0.2827 <0.001 — —
Number of children 13,361
Deaths 370
Person-months of observation 61,045
–2 log likelihood (d.f.) 289.74 (16)
P-value <0.001
a
 Reference category.
Note: Group 0 = No immunizations; Group 1 = Partial BCG/polio/DPT coverage, no measles
vaccine; Group 2 = Full BCG/polio/DPT coverage, no measles vaccine.
20
Table 5 Discrete-time hazards regression model for examining the effect of the degree
of immunization uptake and mortality in the 9–59-month age group
Variable Coefficient Standard error P-value Odds ratio 95% CI
Age (months) –0.0574 0.0080 <0.001 0.94 (0.93, 0.96)
Indicator variables
   Ages 9–11 monthsa 0.0000 — — 1.00 —
   Ages 12–23 months 0.3543 0.3401 0.298 1.43 (0.73, 2.78)
   Ages 24–59 months 0.1265 0.4151 0.761 1.13 (0.50, 2.56)
Vaccination status
   Group 0a 0.0000 — — 1.00 —
   Group 1 –1.0910 0.1733 <0.001 0.34 (0.24, 0.47)
   Group 2 –2.1542 0.2808 <0.001 0.12 (0.07, 0.20)
   Group 3 –2.2752 0.5841 <0.001 0.10 (0.03, 0.32)
   Group 4 –2.1108 0.2451 <0.001 0.12 (0.07, 0.20)
Interaction terms
   Group 1 ×
age 12–23 months 1.1570 0.2141 <0.001 3.18 (2.09, 4.84)
   Group 2 ×
age 12–23 months 2.1785 0.3169 <0.001 8.83 (4.75, 16.44)
   Group 3 ×
age 12–23 months 1.7045 0.6240 0.006 5.50 (1.62, 18.68)
   Group 4 ×
age 12–23 months 1.1019 0.2742 <0.001 3.01 (1.76, 5.15)
   Group 1 ×
age 24–59 months 0.5705 0.2904 0.049 1.77 (1.00, 3.13)
   Group 2 ×
age 24–59 months 1.0107 0.4858 0.037 2.75 (1.06, 7.12)
   Group 3 ×
age 24–59 months 2.0725 0.6436 0.001 7.94 (2.25, 28.05)
   Group 4 ×
age 24–59 months 1.4496 0.2955 <0.001 4.26 (2.39, 7.61)
Sex of child
   Femalea 0.0000 — — 1.00 —
   Male 0.1734 0.0677 0.010 1.19 (1.04, 1.36)
Residence
   Cell 1 0.0810 0.1033 0.433 1.08 (0.89, 1.33)
   Cell 2 –0.1391 0.1129 0.218 0.87 (0.70, 1.09)
   Cell 3 –0.0428 0.0843 0.611 0.96 (0.81, 1.13)
   Cell 4a 0.0000 — — 1.00 —
   Cell 5 –0.6008 0.2132 0.005 0.55 (0.36, 0.83)
continued
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Table 5 continued
Variable Coefficient Standard error P-value Odds ratio 95% CI
Number of compound
residents (log) 0.1482 0.0494 0.003 1.16 (1.05, 1.28)
Mother’s age at birth
of child 0.1507 0.0448 0.001 1.16 (1.06, 1.27)
Mother resident
   Noa 0.0000 — — 1.00 —
   Yes 0.4979 0.3114 0.110 1.65 (0.89, 3.03)
Interaction terms
   Mother resident ×
age 12–23 months –1.1448 0.3399 0.001 0.32 (0.16, 0.62)
   Mother resident ×
age 24–59 months –0.9637 0.3755 0.010 0.38 (0.18, 0.80)
Constant –5.0837 0.3284 <0.001 — —
Number of children 13,452
Deaths 885
Person-months of observation 342,720
–2 log likelihood (d.f.) 727.24 (25)
P-value <0.001
a
 Reference category.
Note: Group 0 = No immunizations; Group 1 = Partial BCG/polio/DPT coverage, no measles
vaccine; Group 2 = Full BCG/polio/DPT coverage, no measles vaccine; Group 3 = Partial BCG/
polio/DPT coverage, measles vaccine; Group 4 = All immunizations (full BCG/polio/DPT cover-
age, measles vaccine).
and not vaccinated against measles (RR comparing Group 3 to Group 1 = 1.27, 95% CI
= [0.73, 2.22]; RR comparing Group 4 to Group 2 = 1.79, 95% CI = [0.83, 3.87]).
Multivariate analysis
The descriptive statistics presented in the previous section must be interpreted
with caution since they cannot account for the fact that children in the various vaccina-
tion status categories may have lower mortality risks than unvaccinated children for
reasons unrelated to their vaccination status. For example, children who have never
been vaccinated may be more likely to live farther away from outreach points or to have
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mothers who are less inclined to use clinical services, both of which would be likely to
put them at higher risk of death during childhood independent of their vaccination sta-
tus. Therefore, multivariate analyses presented below adjust as much as possible for any
such inter-group differences.
A discrete-time hazards model considering only the impact of the BCG/polio/
DPT series on mortality was estimated on children between the ages of 4 and 8 months.
As above, those who received a measles vaccination prior to age 9 months were cen-
sored at the time of vaccination for the purposes of this regression. Also, children who
were older than 4 months at the time of the first vaccination survey were not included.
The regression results are shown in Table 4.
Children with partial and full BCG/polio/DPT coverage have 76 percent and 91
percent reduced odds of mortality, respectively, relative to unvaccinated children after
controlling for age, sex, mother’s age, area of residence, and year of birth. These figures
are similar to the unadjusted rates presented in the previous section. As described above,
other potentially confounding variables were considered and ultimately removed from
the final model if they were neither statistically nor programmatically significant.
A second model comparing all five vaccination status groups was estimated on
children between the ages of 9 and 59 months. Figure 2 indicated that the relationship
between vaccination status and mortality is not constant over this age range. Hence
indicator variables for different age ranges and interaction terms are added to allow
vaccination impact to be age-dependent.
The regression presented in Table 5 models mortality as a linear function of age
and indicates that mortality is decreasing over this age range (odds ratio [OR] = 0.94 per
additional month of age). Indicator variables for age ranges 12–23 months and 24–59
months are added to the model, leaving ages 9–11 months as the reference category.
These variables have the value 1 for the months that the child is in the specified age
group and 0 otherwise. The lack of statistical significance of these indicator variables
indicates that overall levels of mortality do not differ significantly between these age
ranges apart from the general linear decline represented by the first variable.
Given the presence of interaction terms in the model, the coefficients on the vac-
cination status variables should be interpreted as the relationship between vaccination
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status and mortality in the 9–11-month age group only (the reference age group). For
example, the OR of 0.34 for Group 1 indicates that for children 9–11 months old, those
with partial BCG/polio/DPT coverage have 66 percent lower odds of mortality than
unvaccinated children, controlling for other variables.
The coefficients on the interaction terms represent the effect of vaccination status
on mortality in that age group relative to the effect in the 9–11-month age group. To see
the adjusted effect of vaccination on mortality in the 12–23-month and 24–59-month
age groups, we therefore must combine the coefficients on the relevant main effect (e.g.,
Group 1) and interaction (e.g., Group 1 × age 12–23 months) variables. For example, to
understand the relationship of partial BCG/polio/DPT coverage to mortality among 12–
23-month-old children, we add the coefficients for Group 1 and for Group 1 × age 12–
23 months = –1.0910 + 1.1570 = 0.0660. Exponentiation yields an OR of exp(0.0660) =
1.07, which suggests that there is little difference in mortality between Group 1 and
Group 0 in the 12–23-month age group.
Table 6 Adjusted mortality odds ratios (95% confidence intervals) by age group and
vaccination status
Age range (months)
Vaccination status 9–11 12–23 24–59
Group 0a 1.00 1.00 1.00
Group 1 0.34 1.07 0.59
(0.24, 0.47) (0.83, 1.37) (0.38, 0.94)
Group 2 0.12 1.02 0.32
(0.07, 0.20) (0.77, 1.37) (0.15, 0.69)
Group 3 0.10 0.57 0.82
(0.03, 0.32) (0.37, 0.87) (0.48, 1.39)
Group 4 0.12 0.36 0.52
(0.07, 0.20) (0.29, 0.47) (0.37, 0.72)
a
 Reference category.
Note: Group 0 = No immunizations; Group 1 = Partial BCG/polio/DPT coverage, no measles vaccine;
Group 2 = Full BCG/polio/DPT coverage, no measles vaccine; Group 3 = Partial BCG/polio/DPT
coverage, measles vaccine; Group 4 = All immunizations (full BCG/polio/DPT coverage, measles
vaccine).
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To assist with the interpretation of the interaction terms, Table 6 presents ad-
justed mortality ORs based on the regression results in Table 5. The table compares
Groups 1–4 with Group 0 in age ranges 9–11, 12–23, and 24–59 months after control-
ling for confounding variables. The adjusted ORs are similar to the crude RRs inferred
from Figure 2 and presented in Table 3, suggesting that none of the covariates controlled
for in the multivariate analysis significantly confounds the relationship between vacci-
nation status and mortality.
DISCUSSION
The results of our analysis indicate significant reductions in infant and child mor-
tality associated with receipt of BCG, polio, DPT, and measles vaccinations in Kassena-
Nankana District in northern Ghana. Middle post-neonatal mortality (between the ages of
4 and 8 months) is reduced by three-quarters among children who have received some of
the BCG, polio, and DPT vaccinations, and by a remarkable 90 percent for children who
have received all of them. Mortality between 9 months and five years is reduced by one-
third for those who have received BCG, polio, and DPT vaccinations, and by two-thirds
for those who have received the full EPI immunization package (BCG, polio, DPT, and
measles). The incremental reduction in mortality associated with measles vaccination among
children with full BCG, polio, and DPT coverage is approximately 50 percent. These
estimates are unchanged after controlling for potentially confounding background factors.
Our estimate of the all-cause mortality reduction produced by measles vaccina-
tion is consistent with a number of studies from a variety of developing-world settings
(Kristensen, Aaby, and Jensen 2000; Aaby 1995; Koenig et al. 1991). These studies have
consistently shown that measles vaccination campaigns reduce all-cause mortality far in
excess of the proportion of child deaths that can be directly or even indirectly attributed
to measles, prompting speculation that the vaccine may provide nonspecific protective
or immunostimulant benefits. Verbal autopsy data in Navrongo indicate that a mere 3–4
percent of child deaths can be attributed to measles (Binka et al. 1995), and anecdotal
evidence suggests that measles incidence is relatively uncommon now that immuniza-
tion campaigns are inducing high levels of herd immunity.
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Very little research has been published on the effect of the BCG, polio, and DPT
vaccines on all-cause morbidity and mortality. Our results are consistent with a study in
Greifswald, Germany, that randomly allocated children to receive DPT, polio, and hepati-
tis B vaccinations on the first or the thirtieth day of their third month of life. German
guidelines recommend that children receive these vaccinations during their third month,
so both groups were vaccinated as recommended, yet the study design nevertheless per-
mitted a comparison of morbidity between comparable vaccinated and unvaccinated chil-
dren during the third month of life. The study found markedly lower all-cause morbidity
during the third month among those vaccinated at the beginning of the month compared to
those vaccinated at the end (Otto et al. 2000). Our findings are partially at odds with data
recently published by Kristensen, Aaby, and Jensen (2000) from Guinea-Bissau. In their
study, the researchers determined the vaccination status of children 0–6 months of age and
assessed mortality six months later. Children vaccinated against BCG had approximately 50
percent lower mortality than those who had not been vaccinated at the initial visit. However,
those who had received one DPT shot had nearly twice the mortality of those who had not,
after controlling for BCG vaccination status. The mortality of those who had received two or
three DPT shots did not differ significantly from the mortality of the unvaccinated.
This paper does not estimate the effects of BCG, polio, and DPT separately be-
cause of the high correlation between these vaccinations in this study population. DPT
and polio are nearly always administered together, making it practically impossible to
differentiate between their effects. It is extremely rare in Kassena-Nankana District for
a child to be vaccinated against DPT without first having received a BCG shot. Simi-
larly, very few children in our sample received a BCG shot but were not subsequently
vaccinated against DPT. Only 3 percent of those who received a BCG shot did not re-
ceive a DPT vaccination by the age of 12 months. However, despite our inability to
differentiate between the vaccinations, the dramatic reduction in mortality associated
with partial or complete BCG/polio/DPT coverage in this population is clearly not con-
sistent with a deleterious effect of DPT offsetting a beneficial effect of BCG.
Our analysis indicates that even children who receive only part of the EPI pack-
age of immunizations benefit from substantially reduced mortality. While Figure 3b and
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Table 3 show a clear positive trend linking probability of survival with number of vacci-
nations received, even children with only partial BCG/polio/DPT coverage have 25 per-
cent lower mortality than the unvaccinated between the ages of 9 and 59 months, and
nearly 50 percent lower mortality between the ages of 4 and 59 months. These results
suggest that receipt of only part of the EPI package can substantially improve children’s
chances of survival.
Challenges to internal validity are unavoidable in analyses of the all-cause mor-
tality impact of EPI antigens. It would be unethical to conduct randomized controlled
trials of vaccines known to be efficacious in preventing the targeted diseases, apart
from designs such as that used in the study by Otto and colleagues (2000), which can
only examine a narrow window of age in order to satisfy ethical criteria. Vaccinated
children are likely not to be a random sample of all children but rather a select group
that differs from those not vaccinated in many important respects that might also be
expected to influence their mortality risks. While we used multivariate methods to
control as much as possible for differences between vaccinated and unvaccinated chil-
dren, there are likely to be residual unmeasured differences between the two groups
that may be producing these associations. Possible confounding characteristics in-
clude parental preference for the health of their children, the genetically determined
hardiness and health status of the child, and parental attitudes toward modern health
services and health-seeking behavior.
Most of these confounders are difficult to measure in any setting. One confounder
that was considered in this analysis is health-seeking behavior. A 1999 panel survey
among approximately 6,000 women of reproductive age in Kassena-Nankana District
included a module on recent child morbidity and related health-seeking behavior. Ap-
proximately 10 percent of the children in this analysis both had mothers interviewed in
the panel survey and had an episode of illness reported in the panel. An indicator vari-
able was constructed from the responses to this survey to denote whether the mother
sought modern medical treatment for the child during the illness in question, as opposed
to seeking traditional treatment or no treatment at all. When the analysis was restricted
to the subsample for whom the health-seeking behavior variable was defined and this
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variable was included in the discrete-time hazards model, the mortality impact of vacci-
nation status was unchanged. A subsequent analysis indicated that, excluding the health-
seeking behavior variable, the regression produced results in the 10 percent subsample
that were similar to those in the full sample.
A further point of caution must be added with respect to the analyses on the 4–8-
month age group. From Table 1 it is clear that in this age group, the sample used for our
analysis is not representative of all children in Kassena-Nankana District but is heavily
biased toward children more likely to survive. The implications of this bias for the esti-
mate of the relationship between immunization and mortality is unknown. However, if
the reduction in mortality associated with vaccination status is an artifact of the bias in
the sample toward surviving children, we would expect the gap in mortality between
vaccinated and unvaccinated children to narrow as we move from the fourth to the eighth
month of life, since this survival bias decreases in importance at later ages and is absent
for children ages 9 months and older. However, Figures 2a and 2b show a fairly constant
relationship between vaccination status and mortality risk from the fourth through the
eleventh month of life.
The vaccination coverage rates observed for Kassena-Nankana District are much
lower than the target of 90 percent set by UNICEF. The rates, which range from 72
percent for BCG to 45 percent for measles, also fall below those recorded at the national
level. Since 1988 Ghana has recorded an average of over 80 percent for BCG uptake, for
example. The low figures noted for Kassena-Nankana District may be attributed to the
high proportion of births delivered at home and the implications for health-seeking be-
havior. Almost 60 percent of all births in the district occur at home, and these children
usually experience the traditional practice of being kept at home until they are more than
8 days old. Thus, the need to send the child for immunization will depend on how the
mother perceives the program. Some may see it as an inconvenience rather than a neces-
sity. In some situations traditional practitioners give a long list of taboos to new parents
regarding their newborns, including banning the use of needles, with the result that
these children are not taken to a health facility for whatever reason because of the fear
that they will receive injections.
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CONCLUSION
The data on child survival and vaccination status in rural northern Ghana give
strong support to the argument that efforts to implement the Expanded Programme on
Immunization can substantially enhance child survival in high-mortality settings, re-
ducing mortality by up to two-thirds in children who receive the full package relative to
children who have received no vaccinations. Others have argued that such vaccination
programs will eliminate only the proportion of mortality directly attributable to the tar-
geted diseases (Foster 1995) or that they will have no net effect on all-cause mortality
because weak children saved from vaccine-preventable diseases will die of other causes
in health-deprived settings (Mosley and Chen 1984). Our data add to a growing body of
evidence that suggests that measles vaccination programs, in particular, reduce all-cause
mortality substantially beyond the proportion of deaths caused by measles. Our results
also indicate that BCG, polio, and DPT vaccinations substantially reduce under-5 mor-
tality; this is at odds with recent findings from Guinea-Bissau and indicates a need for
further research on the all-cause mortality impact associated with these vaccines in de-
veloping countries. Even children who have received only BCG and one or two shots of
DPT and polio vaccines enjoy substantially lower mortality than unvaccinated children.
In a high-mortality, sub-Saharan African setting with poor infrastructure such as Kassena-
Nankana District, success in delivering even part of the EPI package can yield substan-
tial health dividends.
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